ABSTRACT
When looking at the cost-effectiveness of cancer trials there are several important results that need to be interpreted, both clinically and from a cost-effectiveness perspective. Some of these concepts were introduced earlier, and we will now interpret them with practical examples:
Incremental costs
Incremental QALYs
Interpreting the ICER and the cost-effectiveness plane
Uncertainty analyses
Value of information
